PharmaCyte Biotech (PMCB) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free PMCB Stock Alerts $2.11 -0.01 (-0.47%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024msn.com - December 18 at 12:45 PMCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In Growthfinance.yahoo.com - December 15 at 10:10 AMPharmaCyte Biotech Inc PMCBmorningstar.com - December 5 at 2:20 PMPharmaCyte Biotech Invests In Femasys - Quick Factsmarkets.businessinsider.com - November 15 at 1:20 PMFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotechfinance.yahoo.com - November 15 at 8:20 AMPharmaCyte completes tender offer to purchase sharesmsn.com - June 15 at 2:29 PMPharmaCyte Biotech Announces Final Results of Tender Offerfinance.yahoo.com - June 15 at 9:28 AMLos Angeles Biotech Newsbizjournals.com - June 14 at 1:32 PMPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Sharefinance.yahoo.com - May 11 at 10:07 AMBiotech ETFs’ Performance Deserves A Looknasdaq.com - April 21 at 11:27 PM300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banfortune.com - April 12 at 6:29 PMA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedmsn.com - February 2 at 2:33 PMPharmaCyte Biotech to Implement Second $10-Million Share Repurchase Planfinance.yahoo.com - February 2 at 9:33 AMPharmaCyte to evaluate opportunities; CEO steps downseekingalpha.com - October 7 at 5:11 PMPharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps Downmarkets.businessinsider.com - October 7 at 12:10 PMPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capitalfinance.yahoo.com - August 15 at 10:23 AMIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.finance.yahoo.com - July 28 at 12:24 PMPharmaCyte Biotech Commences First Phase of Two-Phase Pig Studyfinance.yahoo.com - July 21 at 9:26 AMIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSfinance.yahoo.com - July 11 at 8:51 AMPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022finance.yahoo.com - July 11 at 8:51 AMPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cellsfinance.yahoo.com - July 5 at 9:34 AMIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGfinance.yahoo.com - June 23 at 6:15 PMPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Valuestockhouse.com - June 17 at 7:07 PMPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Valuefinance.yahoo.com - June 15 at 10:30 AMPharmaCyte Biotech to Attend 2022 BIO International Convention in San Diegofinance.yahoo.com - June 13 at 9:14 AMPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Valuefinance.yahoo.com - June 8 at 9:47 AMPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetesfinance.yahoo.com - April 27 at 2:16 PMPharmaCyte Biotech Shares Reverse Course, Drop 8%marketwatch.com - April 19 at 2:46 PMPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirementsfinance.yahoo.com - April 19 at 9:37 AMPharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical holdseekingalpha.com - April 13 at 2:04 PMPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trialfinance.yahoo.com - April 13 at 9:04 AMPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directorsfinance.yahoo.com - April 5 at 10:49 AMPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidatefinance.yahoo.com - March 22 at 5:45 PMPharmaCyte Biotech (OTCMKTS:PMCB) Raised to Buy at Zacks Investment Researchmarketbeat.com - March 19 at 4:39 AMPharmaCyte Biotech reports Q3 resultsseekingalpha.com - March 18 at 6:56 AMPharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlightsfinance.yahoo.com - March 16 at 10:48 AMPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integrationfinance.yahoo.com - February 22 at 4:56 PMPharmaCyte Biotech (OTCMKTS:PMCB) Downgraded by Zacks Investment Researchmarketbeat.com - February 16 at 3:43 AMPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDAfinance.yahoo.com - February 14 at 10:08 AMPharmaCyte Biotech (OTCMKTS:PMCB) Upgraded to "Buy" by Zacks Investment Researchmarketbeat.com - January 11 at 9:28 AMPharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cellsfinance.yahoo.com - January 4 at 12:37 PMPharmaCyte Biotech Reports Q2 2021 Cash On Hand $87Mbenzinga.com - December 16 at 8:39 PMPharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlightsfinance.yahoo.com - December 15 at 1:49 PM5 Penny Stocks With Long-Term Growth Catalystsinsidermonkey.com - October 5 at 10:09 AMPharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNAfinance.yahoo.com - September 27 at 2:19 PMPharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Testsfinance.yahoo.com - September 21 at 1:13 PMThinking about buying stock in Camber Energy, Farmmi, Offerpad Solutions, Pharmacyte Biotech, or Barrick Gold?benzinga.com - September 16 at 1:20 PMPharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDAfinance.yahoo.com - September 16 at 1:20 PMThinking about buying stock in Globalstar, Pharmacyte Biotech, Humanigen, Kadmon Holdings, or Camber Energy?morningstar.com - September 9 at 4:26 PMPharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conferencefinance.yahoo.com - September 8 at 9:44 AM Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> PMCB Media Mentions By Week PMCB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMCB News Sentiment▼1.000.32▲Average Medical News Sentiment PMCB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMCB Articles This Week▼10▲PMCB Articles Average Week Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: APTO News Today AIM News Today EVAX News Today SNTI News Today ZIVO News Today COEP News Today IKT News Today BCDA News Today PLUR News Today ONVO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMCB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
